The family faced an agonizing decision: continue fundraising for a treatment that might no longer work, or pivot to palliative care. They chose to press on. “As long as Chisa is fighting, we fight,” her mother told ITV News in September 2021. By October 2021, the campaign had stalled at £1.45 million. Short by £350,000. The Chicago hospital declined to offer a discount. Desperate, the family launched a last-minute auction, selling heirlooms and even a car donated by a local dealer. On November 15, 2021, they announced they had reached the goal—£1,800,032. The news made the BBC’s local headlines.
Moreover, the treatment itself carried no guarantee of success. In their fundraising appeals, Chisa’s parents were transparent: “We cannot promise that this treatment will cure her. But we can promise that without it, she has no chance.” That brutal honesty resonated with donors but also introduced a layer of moral hesitation. Some potential supporters asked: “What if we give £10,000 and she still doesn’t make it?” Charitable fatigue is real, especially when outcomes are uncertain. Unlike countries with mandatory catastrophic health insurance, England’s healthcare system is centralized. The NHS’s Highly Specialised Technologies (HST) program evaluates rare-disease treatments based on cost-effectiveness (measured in QALYs—Quality-Adjusted Life Years). If a treatment costs more than £300,000 per QALY gained, it is almost always rejected. For Chisa’s treatment, the cost per QALY exceeded £1.2 million. The NHS said no. eng raising funds for chisas treatment uncen 2021
If you take one thing from this article, let it be this: when you see a medical fundraising appeal, your donation is never just money. It is a vote against uncertainty. And sometimes, even when the outcome is uncertain, the act of trying is the only thing that separates humanity from despair. If you or someone you know is facing a similar situation in England, resources such as the Rare Disease UK (RDUK) network, the “Just4Children” fund, and the “Tree of Hope” charity offer guidance for ethical medical fundraising. The family faced an agonizing decision: continue fundraising
But medical uncertainty does not vanish with money. A pre-travel assessment in early December 2021 revealed that Chisa’s liver enzymes were dangerously high. The Chicago team said she was no longer a candidate for the gene therapy protocol. The treatment had become uncertain in the worst possible way: unavailable. By October 2021, the campaign had stalled at £1